bioRxivPathologyPreprint
A review of diagnostic approaches to medullary thyroid carcinoma
Abstract
Medullary thyroid carcinoma (MTC), occurring sporadically or as an autosomal dominant trait, accounts for 5-10% of all thyroid gland neoplasms. While the sporadic variant originates from somatic rearranged-during-transfection (RET) mutations, the inherited variant is preceded by germ-line mutations of the RET proto-oncogene. Analysis of the transformations of this certain gene is the cornerstone of diagnostic and prognostic approaches in MTC. Additionally, a panel of histopathological evaluations, biochemical markers, and imaging procedures play a pivotal role in the management of MTC. The survival rate of MTC is relatively low compared to differentiated thyroid neoplasia and is highly influenced by the stage of tumors. Improvement in MTC surveillance significantly depends on early diagnosis as well as implementation of proper screening modalities in hereditary subtypes. The present review addresses medullary thyroid carcinoma, and in particular, the current diagnostic approaches to this challenging malignancy.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Patient-Derived Medullary Thyroid Cancer Organoids; a Model for Patient-tailored Drug and PET-Tracer Screening
L. H. J. Sondorp, E. C. Jager, … S. Kruijff·bioRxiv·Sep 18, 2023
- Familial medullary thyroid carcinoma secondary to an SLC30A9 intragenic deletion and translation reinitiation
Donato Iacovazzo, Federica Begalli, … Márta Korbonits·medRxiv·Feb 27, 2026
- Telomere maintaining germline and somatic variants in thyroid cancer and melanoma
Sandya Liyanarachchi, Pamela L. Brock, … Matthew David Ringel·medRxiv·May 25, 2026
- Activating RET Mutations Promotes Osteoblastic Bone Metastases in Medullary Thyroid Cancer
Rozita Bagheri‐Yarmand, Gabriel M. Pagnotti, … Theresa A. Guise·bioRxiv·Jul 9, 2025
- Drugging the Medullary Thyroid Cancer Surfaceome with T Cell Engagers Targeting CEA, GFRA4 and DLL3 as Monotherapy and In Combination with Tyrosine Kinase Inhibitors
Tim Andrew Erickson·bioRxiv·Aug 5, 2025
- THE MITOCHONDRIAL DNA CONTROL REGION MIGHT HAVE USEFUL DIAGNOSTIC AND PROGNOSTIC BIOMARKERS FOR THYROID TUMORS
R. Bircan, H. Iliksu Gozu, … C. Aral·bioRxiv·Mar 29, 2018